Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2001

View Archived Issues

Amrad product pipeline update

2000 highlights reported for Cell Therapeutics

Shire reviews Q4 and year-end 2000 developments

Two studies demonstrate efficacy of ziprasidone in patients with schizoaffective disorder

Demegen's antimicrobial peptide shows efficacy against herpesviruses and Chlamydia

Antiinfective properties of Pharming's hLF reported; AM-Pharma licenses Pharming peptide technology

Cellegy accelerates filing for Anogesic in Canada

Ribozyme and Chiron begin phase II trial with Angiozyme for breast cancer

Botulinum toxin type A preparation proves safe and effective in axillary hyperhidrosis

Update on phase II trials with Nobex's oral insulin reported

Promising toxicity and pharmacokinetic findings emerge from phase Ia trial of doranidazole

Orally active small-molecule GnRH antagonists presented by Neurocrine Biosciences

Review of Aslera NDA rescheduled for April

Pentasaccharide registration submission and other important events at Sanofi-Synthelabo

Access reports positive phase III data for OraDisc canker sore treatment

AtheroGenics moves second product into clinical development

Phase II trials of SMART 1D10 antibody begin in non-Hodgkin's lymphoma

BASB113 polynucleotides and polypeptides for use as vaccines

Chlamydia polypeptide and use in DNA vaccines

Antibacterial quinolinecarboxylic acid derivatives in development at Wakunaga

Taisho presents new VEGF receptor antagonists with antiangiogenic/antitumor activity

Hybrigenics and Servier to identify new targets for anticancer drugs

New treatments for osteoporosis with an indole structure

Merck reports compounds with the ability to inhibit cytokine production or activity

Recent patent covers metabotropic glutamate receptor antagonists selective for group II/III

Sigma receptor ligands and use as antipsychotics, etc., reported by Sanofi-Synthelabo

Dihydrobenzodiazepines and use in dyslipidemias, diabetes, etc.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...